Maintenance Regorafenib Significantly Delays Disease Progression After First-Line Treatment in Patients with Advanced Non-Adipocytic Soft Tissue Sarcomas By Ogkologos - April 28, 2025 810 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EREMISS study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Machine Learning-Based Model Shows Promise for Indicating Response to Immune Checkpoint... December 9, 2020 ENLACE Study Explores Colorectal Cancer in Hispanic and Latino People October 18, 2023 Police Officer Has Bulletproof Vest to Thank for Helping Her Discover... June 23, 2021 Cancer in My Community: Expanding Genetic Testing in Thailand October 11, 2022 Load more HOT NEWS 120 years of discovery: 10 ways we’ve changed the story for... FDA Approves Osimertinib with Platinum-Based Chemotherapy for EGFR-mutated Locally Advanced or... FDA Grants Accelerated Approval to Selpercatinib for Paediatric Patients Two Years... Reduction Not Only in Recurrences, but Also in Mortality, Observed for...
